Cargando…
The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy
BACKGROUND: Previously identified risk factors for psoriatic arthritis (PsA); nail dystrophy and scalp lesions are highly prevalent in patients with moderate-to-severe psoriasis. Therefore, these variables may not be useful as predictors for PsA in this population. OBJECTIVE: We assessed the predict...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547182/ https://www.ncbi.nlm.nih.gov/pubmed/33117661 http://dx.doi.org/10.2147/PTT.S270619 |
_version_ | 1783592374317875200 |
---|---|
author | van Muijen, Marloes E van Hal, Tamara W Groenewoud, Hans M M van den Reek, Juul M P A de Jong, Elke M G J |
author_facet | van Muijen, Marloes E van Hal, Tamara W Groenewoud, Hans M M van den Reek, Juul M P A de Jong, Elke M G J |
author_sort | van Muijen, Marloes E |
collection | PubMed |
description | BACKGROUND: Previously identified risk factors for psoriatic arthritis (PsA); nail dystrophy and scalp lesions are highly prevalent in patients with moderate-to-severe psoriasis. Therefore, these variables may not be useful as predictors for PsA in this population. OBJECTIVE: We assessed the predictive value of demographic and clinical characteristics for development of PsA in a cohort of patients with moderate-to-severe psoriasis, currently treated with biologics. Furthermore, we reported the incidence of new-onset PsA in this population and described the characteristics of patients that developed PsA during biologic treatment. METHODS: Demographics and treatment characteristics of psoriasis patients currently using biologic therapy were extracted from the BioCAPTURE database (n=427). Poisson regression was used to calculate incidence rates. Multivariable logistic regression was performed to identify factors independently associated with PsA onset. Patient and treatment characteristics of patients that developed PsA during biologic treatment were described. RESULTS: The incidence of PsA was 1.0 (95% CI 0.8–1.2) per 100 psoriasis-years. Except for a lower risk for PsA in male gender (OR 0.58, 95% CI 0.34–0.98, p-value 0.04), no clinical factors were significantly associated with an altered risk of developing PsA. During biologic therapy, 32 patients (9.4%) newly developed PsA. In this group, 53.8% had PASI<5 at PsA diagnosis. The incidence rate of PsA was 1.6 (95% CI 1.1–2.2) per 100 years on biologic therapy. CONCLUSION: Clinical risk factors might be inaccurate to predict PsA onset in patients with moderate-to-severe psoriasis on biologics. Even with low disease activity, psoriasis patients on biologics are still prone to develop PsA. |
format | Online Article Text |
id | pubmed-7547182 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75471822020-10-27 The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy van Muijen, Marloes E van Hal, Tamara W Groenewoud, Hans M M van den Reek, Juul M P A de Jong, Elke M G J Psoriasis (Auckl) Original Research BACKGROUND: Previously identified risk factors for psoriatic arthritis (PsA); nail dystrophy and scalp lesions are highly prevalent in patients with moderate-to-severe psoriasis. Therefore, these variables may not be useful as predictors for PsA in this population. OBJECTIVE: We assessed the predictive value of demographic and clinical characteristics for development of PsA in a cohort of patients with moderate-to-severe psoriasis, currently treated with biologics. Furthermore, we reported the incidence of new-onset PsA in this population and described the characteristics of patients that developed PsA during biologic treatment. METHODS: Demographics and treatment characteristics of psoriasis patients currently using biologic therapy were extracted from the BioCAPTURE database (n=427). Poisson regression was used to calculate incidence rates. Multivariable logistic regression was performed to identify factors independently associated with PsA onset. Patient and treatment characteristics of patients that developed PsA during biologic treatment were described. RESULTS: The incidence of PsA was 1.0 (95% CI 0.8–1.2) per 100 psoriasis-years. Except for a lower risk for PsA in male gender (OR 0.58, 95% CI 0.34–0.98, p-value 0.04), no clinical factors were significantly associated with an altered risk of developing PsA. During biologic therapy, 32 patients (9.4%) newly developed PsA. In this group, 53.8% had PASI<5 at PsA diagnosis. The incidence rate of PsA was 1.6 (95% CI 1.1–2.2) per 100 years on biologic therapy. CONCLUSION: Clinical risk factors might be inaccurate to predict PsA onset in patients with moderate-to-severe psoriasis on biologics. Even with low disease activity, psoriasis patients on biologics are still prone to develop PsA. Dove 2020-10-05 /pmc/articles/PMC7547182/ /pubmed/33117661 http://dx.doi.org/10.2147/PTT.S270619 Text en © 2020 van Muijen et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research van Muijen, Marloes E van Hal, Tamara W Groenewoud, Hans M M van den Reek, Juul M P A de Jong, Elke M G J The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy |
title | The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy |
title_full | The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy |
title_fullStr | The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy |
title_full_unstemmed | The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy |
title_short | The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy |
title_sort | skin may clear but the arthritis won’t disappear: focusing on concomitant and new-onset psoriatic arthritis in a daily practice cohort of psoriasis patients on biologic therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547182/ https://www.ncbi.nlm.nih.gov/pubmed/33117661 http://dx.doi.org/10.2147/PTT.S270619 |
work_keys_str_mv | AT vanmuijenmarloese theskinmayclearbutthearthritiswontdisappearfocusingonconcomitantandnewonsetpsoriaticarthritisinadailypracticecohortofpsoriasispatientsonbiologictherapy AT vanhaltamaraw theskinmayclearbutthearthritiswontdisappearfocusingonconcomitantandnewonsetpsoriaticarthritisinadailypracticecohortofpsoriasispatientsonbiologictherapy AT groenewoudhansmm theskinmayclearbutthearthritiswontdisappearfocusingonconcomitantandnewonsetpsoriaticarthritisinadailypracticecohortofpsoriasispatientsonbiologictherapy AT vandenreekjuulmpa theskinmayclearbutthearthritiswontdisappearfocusingonconcomitantandnewonsetpsoriaticarthritisinadailypracticecohortofpsoriasispatientsonbiologictherapy AT dejongelkemgj theskinmayclearbutthearthritiswontdisappearfocusingonconcomitantandnewonsetpsoriaticarthritisinadailypracticecohortofpsoriasispatientsonbiologictherapy AT vanmuijenmarloese skinmayclearbutthearthritiswontdisappearfocusingonconcomitantandnewonsetpsoriaticarthritisinadailypracticecohortofpsoriasispatientsonbiologictherapy AT vanhaltamaraw skinmayclearbutthearthritiswontdisappearfocusingonconcomitantandnewonsetpsoriaticarthritisinadailypracticecohortofpsoriasispatientsonbiologictherapy AT groenewoudhansmm skinmayclearbutthearthritiswontdisappearfocusingonconcomitantandnewonsetpsoriaticarthritisinadailypracticecohortofpsoriasispatientsonbiologictherapy AT vandenreekjuulmpa skinmayclearbutthearthritiswontdisappearfocusingonconcomitantandnewonsetpsoriaticarthritisinadailypracticecohortofpsoriasispatientsonbiologictherapy AT dejongelkemgj skinmayclearbutthearthritiswontdisappearfocusingonconcomitantandnewonsetpsoriaticarthritisinadailypracticecohortofpsoriasispatientsonbiologictherapy |